SU2C Phillip A. Sharp Innovation in Collaboration Awards

Collaboration among scientists and different institutions is one of the hallmarks of Stand Up To Cancer. To encourage this, SU2C awards grants every year to scientists on different teams within the SU2C research community who propose new and potentially fruitful ways of working with each other. These Phillip A. Sharp Innovation in Collaboration Awards are named after the Nobel Laureate and Chair of the SU2C Scientific Advisory Committee, who has always insisted on a high level of collaboration within SU2C’s work. 

Meet the active SU2C Sharp Award Recipients  

Luis A. Diaz, Jr. MD/Florencia McAllister, MD “Genomic and therapeutic implications of selective bacterial and fungal malignancies”  

Phillip A. Greenberg, MD/William A. Freed-Pastor, MD “Utilizing tumor organoids to facilitate the development of effective strategies to target pancreatic cancer with engineered T cells“

David G. Kirsch, MD, PhD/Michal Sheffer, PhD “Harnessing NK cells to treat pediatric cancers” 

Karin Pelka, PhD/Matthew D. Hellman, MD “Can scRNAseq-derived gene programs predict anti-PD-1 response in high TMB CRC and NSCLC patients?” 

Poul Sorensen, MD, PhD/Elizabeth R. Lawlor, MD, PhD. “Enhancing ferroptosis to block Ewing sarcoma metastatic capacity”  

2019 RECIPIENTS 

Alan D. D’Andrea, MD/Juan R. Cubillos-Ruiz, PhD “Resistance to PARP inhibitor plus anti-PD1 therapy driven by ER stress and bioactive lipids in ovarian cancer” 

Maximilian Diehn, PhD/Aaron N. Hata, MD, PhD “Non-invasive monitoring of tumor phenotype by interrogation of plasma cell free tumor RNA” 

Sarah K. Tasian, MD/Kimberly Stegmaier, MD “Precision of combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR1) signaling in pediatric and adult CRLF2-rearranged ALL” 

Robert H. Vonderheide, MD, DPhil/Vinod P. Balachandran, MD “Antigenicity of mutant Kras and impact on cancer evolution” 

2018 RECIPIENTS 

Claire F. Friedman, MD/Marta Łuksza, PhD “Defining effective T-cell response in viral and non-viral gynecologic cancers”